Dr. O'Connor on Real-World Results With Regorafenib in mCRC

Juan Manuel O'Connor, MD
Published: Monday, Nov 12, 2018



Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses real-world results with regorafenib (Stivarga) in the treatment of patients with metastatic colorectal cancer (mCRC).

In a presentation of the final results from the prospective, observational CORRELATE study at the 2018 ESMO Congress, real-world dosing data were revealed for regorafenib in patients with mCRC. Of the 1037 patients eligible for evaluation, results indicated that 57% started treatment at 160 mg, 30% of patients began at 120 mg, and 13% began at ≤80 mg.

The take-home message of the study, says O’Connor, is that despite the differences in starting dose, there was no impact on the median overall survival and median progression-free survival. Moving forward, it is important to consider data from the real-world setting, states O’Connor, as there may be differences in the data demonstrated in clinical trials versus the clinic.
SELECTED
LANGUAGE


Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses real-world results with regorafenib (Stivarga) in the treatment of patients with metastatic colorectal cancer (mCRC).

In a presentation of the final results from the prospective, observational CORRELATE study at the 2018 ESMO Congress, real-world dosing data were revealed for regorafenib in patients with mCRC. Of the 1037 patients eligible for evaluation, results indicated that 57% started treatment at 160 mg, 30% of patients began at 120 mg, and 13% began at ≤80 mg.

The take-home message of the study, says O’Connor, is that despite the differences in starting dose, there was no impact on the median overall survival and median progression-free survival. Moving forward, it is important to consider data from the real-world setting, states O’Connor, as there may be differences in the data demonstrated in clinical trials versus the clinic.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x